Use of inhibitors of ATP-sensitive potassium channels for the treatment of hearing loss

摘要

The use of inhibitors of ATP-sensitive potassium channels for the protective (including preventive) therapy or the reduced progression of hearing loss, in particular age-related hearing loss (presbycusis). Preferred is the systemic or local administra­tion of clinically established sulfonylureas, such as, for example, glibenclamide. The administration may be oral, topical, subcutaneous or by injection.